Skip to Content

Benazepril / hydrochlorothiazide Pregnancy and Breastfeeding Warnings

Benazepril / hydrochlorothiazide is also known as: Lotensin HCT

Medically reviewed on Oct 2, 2017

Benazepril / hydrochlorothiazide Pregnancy Warnings

Animal studies have failed to reveal evidence of teratogenicity. In humans, use of drugs that act on the renin angiotensin system during the second and third trimesters increases fetal and neonatal morbidity and death. There are no controlled data in human pregnancy.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should not be used during pregnancy unless there are no alternatives and the benefit outweighs the risk to the fetus.

US FDA pregnancy category: D

Comments: Adequate methods of contraception should be encouraged.

See references

Benazepril / hydrochlorothiazide Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Yes (benazepril [in small amounts], hydrochlorothiazide)

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Lotensin HCT (benazepril-hydrochlorothiazide)." Ciba Pharmaceuticals, Summit, NJ.

References for breastfeeding information

  1. "Product Information. Lotensin HCT (benazepril-hydrochlorothiazide)." Ciba Pharmaceuticals, Summit, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide